| Date | Title | Description |
| 02.06.2025 | Paradigm Shift in MDS Treatment: Faron Pharmaceuticals Unveils Landmark Phase II Trial Data at ASCO 2025 The ability to not only extend life but also improve quality of life by reducing transfusion ne... | In a field long hindered by stagnation, Faron Pharmaceuticals may have just turned a critical corner in the fight against high-risk myelodysplastic syndromes (HR-MDS). The Finnish clinical-stage biopharmaceutical company unveiled highly pro... |
| 13.12.2024 | Faron’s Financial Calendar for 2025 | Faron’s Financial Calendar for 2025
Fri, Dec 13, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron’s Financial Calendar for 2025
Company announcement, 13 December 2024
TURKU, FINLAND - Faron Phar... |
| 10.12.2024 | Faron presents BEXMAB data at ASH Annual Meeting | Faron presents BEXMAB data at ASH Annual Meeting
Tue, Dec 10, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron Presents Full Analysis of Positive Phase 2 Interim Data from BEXMAB Trial at the 66... |
| 02.12.2024 | Interactions with UK Regulatory Authorities | Interactions with UK Regulatory Authorities
Mon, Dec 02, 2024 09:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron Announces Positive Update on Recent Interactions with UK Regulatory Authorities regardin... |
| 27.11.2024 | Positive Phase 2 Interim Results from BEXMAB Trial | Positive Phase 2 Interim Results from BEXMAB Trial
Wed, Nov 27, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Inside Information: Faron Announces Positive Phase 2 Interim Results from BEXMAB Trial ... |
| 11.11.2024 | Faron Pharmaceuticals: Pioneering New Frontiers in Autoimmune Disease Treatment | Faron Pharmaceuticals Ltd. is making waves in the biopharmaceutical world. This clinical-stage company, based in Turku, Finland, is focused on immunotherapy, a beacon of hope in the fight against cancer and autoimmune diseases. Their latest... |
| 11.11.2024 | Targeting Soluble Clever-1 for Autoimmune Diseases | Targeting Soluble Clever-1 for Autoimmune Diseases
Mon, Nov 11, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Pipeline Update: Targeting Soluble Clever-1 for Autoimmune Diseases
Press release, 11 N... |
| 05.11.2024 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Tue, Nov 05, 2024 08:00 CET Report this content
(“Faron” or “the Company”)
Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Company Announcement, 5 Nov... |
| 22.10.2024 | Faron’s Capital Markets Day 2024 | Faron’s Capital Markets Day 2024
Tue, Oct 22, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron’s Capital Markets Day 2024 – BEXMAB follow-up data and update on drug development pipeline, partner... |
| 07.10.2024 | Faron announces Capital Markets Day | Faron announces Capital Markets Day
Mon, Oct 07, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron announces Capital Markets Day to be held on 22 October 2024
Press release, 7 October 2024
TURKU,... |
| 30.08.2024 | Grant of options | Grant of options
Fri, Aug 30, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Grant of options
Company announcement, August 30, 2024
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First Nort... |
| 29.08.2024 | Faron Pharmaceuticals: A New Dawn in Cancer Treatment | Faron Pharmaceuticals Ltd. is making waves in the biopharmaceutical ocean. The company, based in Turku, Finland, is on a mission to tackle aggressive cancers with its innovative immunotherapy, bexmarilimab. Recent developments have position... |
| 27.08.2024 | Faron 2024 Half-Year Financial Results | Faron 2024 Half-Year Financial Results
Tue, Aug 27, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron Reports Half-Year Financial Results, 1 January – 30 June 2024
Company Announcement, 27 August... |
| 26.08.2024 | FDA Grants Fast Track Designation for Bexmarilimab | FDA Grants Fast Track Designation for Bexmarilimab
Mon, Aug 26, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS
Compa... |
| 20.08.2024 | Notice of Half-Year Financial Results | Notice of Half-Year Financial Results
Tue, Aug 20, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron Pharmaceuticals
Notice of Half-Year Financial Results
Company Announcement, 20 August 2024
TUR... |
| 13.08.2024 | Traumakine Research Collaboration and DoD Grant | Traumakine Research Collaboration and DoD Grant
Tue, Aug 13, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron Announces Traumakine Research Collaboration and DoD Grant
Press release, 13 August 2... |
| 13.08.2024 | Duquesne Receives New $1.5 Million Grant to Expand Transplantation Research | PITTSBURGH, Aug. 13, 2024 /PRNewswire/ -- Duquesne University has received a new $1.5 million grant that will expand research into using nanoparticle technology to preserve human limbs for transplantation surgeries.
The grant awarded to Dr.... |
| 08.08.2024 | Appointment of Chief Financial Officer | Appointment of Chief Financial Officer
Thu, Aug 08, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Appointment of Chief Financial Officer
Company announcement, 8 August 2024 at 2:00 a.m. EDT / 7:00 ... |
| 07.08.2024 | The Rise of Battery Banks: A New Era in Electric Vehicle Infrastructure | The electric vehicle (EV) revolution is upon us. As cities grow greener and technology advances, the need for efficient energy solutions becomes paramount. Enter battery banks—a concept that promises to reshape the landscape of EV infrastru... |
| 07.08.2024 | Grant of options | Grant of options
Wed, Aug 07, 2024 11:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Grant of options
Company announcement, August 7, 2024 at 10.00 a.m. BST / 12:00 p.m. EEST
TURKU, FINLAND - Faron Pharmace... |
| 06.08.2024 | Faron Appoints Dr. Petri Bono as new CMO | Faron Appoints Dr. Petri Bono as new CMO
Tue, Aug 06, 2024 09:30 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron Appoints Dr. Petri Bono as new CMO
Company announcement, 6 August 2024 at 8:30 a.m. BST / 1... |
| 11.07.2024 | Faron Announces Positive FDA Feedback | Faron Announces Positive FDA Feedback
Thu, Jul 11, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside Information: Faron Announces Positive FDA Feedback
Company announcement, Inside Information, ... |
| 25.06.2024 | Update on settlement | Update on settlement
Tue, Jun 25, 2024 15:00 CET Report this content
Faron Pharmaceuticals Ltd
(“Faron” or the “Company”)
Update on settlement under the UK Open Offer and the REX Retail Offer
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DI... |
| 20.06.2024 | New shares registered with Finnish Trade Register | New shares registered with Finnish Trade Register
Thu, Jun 20, 2024 14:00 CET Report this content
Faron Pharmaceuticals Ltd
(“Faron” or the “Company”)
New shares of Faron registered with the Finnish Trade Register
NOT FOR RELEASE, PUBLICATI... |
| 20.06.2024 | Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering | Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering
Thu, Jun 20, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd
(“Faron” or the “Company”)
Inside Information: Faron publ... |
| 05.06.2024 | Proposed REX Retail Offer | Proposed REX Retail Offer
Wed, Jun 05, 2024 09:00 CET Report this content
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR WITHIN THE UNITED STATES... |
| 04.06.2024 | Faron commences a share offering | Faron commences a share offering
Tue, Jun 04, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd
(“Faron” or the “Company”)
Inside Information: Faron commences a share offering of preliminarily a maximum of 30,714,592 Offer Shares... |
| 29.05.2024 | Finnish biology inventors selected as finalists for the European Inventor Award 2024 | Finnish biology inventors selected as finalists for the European Inventor Award 2024
Wed, May 29, 2024 06:30 CET Report this content
The husband-and-wife team, Sirpa and Markku Jalkanen, developed a clinical treatment to activate the immune... |
| 20.05.2024 | Initial positive data from Phase 2 of BEXMAB | Initial positive data from Phase 2 of BEXMAB
Mon, May 20, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside Information: Faron Reports Initial Positive Phase 2 Read-out in HMA-resistant MDS
Comp... |
| 17.05.2024 | Issuance of warrants | Issuance of warrants
Fri, May 17, 2024 17:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Issuance of warrants
Company Announcement, 17 May 2024 at 18:00 (EEST) / 16:00 (BST) / 11:00 AM (EDT)
TURKU, FINLAND / ... |
| 16.05.2024 | Founders named European Inventor Award finalists | Founders named European Inventor Award finalists
Thu, May 16, 2024 08:05 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Faron founders and bexmarilimab developers selected as finalists for the European Inventor ... |
| 13.05.2024 | Replacement – Board Change | Replacement – Board Change
Mon, May 13, 2024 08:00 CET Report this content
The following amendment has been made to the ’Board Change ' announcement released on 30 April 2024 at 1:00 PM (BST) under RNS No. 6380M.
Juho Jalkanen was appointed... |
| 30.04.2024 | Board Change | Board Change
Tue, Apr 30, 2024 14:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Board Change
Company announcement, April 30, 2024 at 15:00 (EEST) / 1:00 PM (BST) / 8:00 AM (EDT)
TURKU, FINLAND / BOSTON, MA... |
| 30.04.2024 | Update on financial status | Update on financial status
Tue, Apr 30, 2024 15:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Inside Information: Update on financial status Further cash preservation extends runway into Q3/2024 Understandin... |
| 16.04.2024 | Faron confirms plans under new leadership | Faron confirms plans under new leadership
Tue, Apr 16, 2024 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Faron confirms plans for the coming months under new leadership
- Initial data from ongoing Phase ... |
| 15.04.2024 | Appointment of Chief Financial Officer | Appointment of Chief Financial Officer
Mon, Apr 15, 2024 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or the “Company”)
Insider Information: Appointment of Chief Financial Officer
Company announcement, Inside information
1... |
| 08.04.2024 | Decisions of the Board of Directors | Decisions of the Board of Directors
Mon, Apr 08, 2024 08:05 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or the “Company”)
Decisions of the Board of Directors
Company announcement, April 8, 2024 at 9:05 (EEST) / 7:05 AM (GMT) / ... |
| 08.04.2024 | Appointment of Chief Executive Officer | Appointment of Chief Executive Officer
Mon, Apr 08, 2024 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or the “Company”)
Appointment of Chief Executive Officer
Company announcement, April 8, 2024 at 9:00 (EEST) / 7:00 AM (B... |
| 08.04.2024 | Approval of Warrant Terms and Conditions | Approval of Warrant Terms and Conditions
Mon, Apr 08, 2024 08:10 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Approval of Warrant Terms and Conditions
Company announcement, April 8, 2024 at 12:10 AM (EDT) / 7:10 A... |
| 05.04.2024 | Results of the Annual General Meeting | Results of the Annual General Meeting
Fri, Apr 05, 2024 13:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or the “Company”)
Results of the Annual General Meeting
Change of Directors
Company announcement, 5 April 2024 at 14:00 (... |
| 04.04.2024 | Announcement of Placing | Announcement of Placing
Thu, Apr 04, 2024 08:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, I... |
| 26.03.2024 | Faron´s Annual Report 2023 | Faron´s Annual Report 2023
Tue, Mar 26, 2024 11:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron´s Annual Report 2023
Company announcement, March 26, 2024
TURKU, Finland / BOSTON, Mass... |
| 18.03.2024 | Additional Positive Data from Phase 1 of BEXMAB | Additional Positive Data from Phase 1 of BEXMAB
Mon, Mar 18, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in ... |
| 14.03.2024 | Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab | - |
| 14.03.2024 | Faron to Host BEXMAB Webcast | Faron to Host BEXMAB Webcast
Thu, Mar 14, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron to Host Webcast to Discuss Latest Data from Phase 1 Part of the BEXMAB Study of Bexmarilimab
Press Rele... |
| 13.03.2024 | Notice of Annual General Meeting 2024 | Notice of Annual General Meeting 2024
Wed, Mar 13, 2024 15:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Notice of Annual General Meeting 2024
Company announcement on March 13, 2024 at 14:00 GMT / 16:00 EET
NOTI... |
| 13.03.2024 | Faron’s Financial Statement Release January 1 to December 31, 2023 | - |
| 13.03.2024 | Financial Statement January 1 to December 31 2023 | Financial Statement January 1 to December 31 2023
Wed, Mar 13, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron’s Financial Statement Release January 1 to December 31, 2023
Financial statement r... |
| 28.02.2024 | Replacement - Update to 2024 Financial Calendar | Replacement - Update to 2024 Financial Calendar
Wed, Feb 28, 2024 17:00 CET Report this content
The following amendments have been made to the 'Update to Faron’s Financial Calendar for 2024' announcement released on 27 February 2024 at 1:00... |
| 27.02.2024 | Update to Faron’s Financial Calendar for 2024 | Update to Faron’s Financial Calendar for 2024
Tue, Feb 27, 2024 19:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Update to Faron’s Financial Calendar for 2024
Company announcement February 27, 2024 at 1:00 p.m. ... |
| 21.02.2024 | Continued Negotiations Regarding Events of Default | Continued Negotiations Regarding Events of Default
Wed, Feb 21, 2024 15:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART... |
| 19.02.2024 | Events of Default | Events of Default
Mon, Feb 19, 2024 11:30 CET Report this content
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE EU REGULATION 596/2014 ("MAR") AND ARTICLE 7 OF MAR AS IT FORMS PART OF DOMESTIC ... |
| 25.01.2024 | BEXMAB Insights into Patient Profiles | BEXMAB Insights into Patient Profiles
Thu, Jan 25, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MD... |
| 19.01.2024 | Exercise of options | Exercise of options
Fri, Jan 19, 2024 14:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron”)
Exercise of options
Issue of equity
Company announcement, January 19, 2024, at 1:00 p.m. GMT / 3:00 p.m. EET
TURKU, FINLAND / BOSTON, M... |
| 09.01.2024 | Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial | Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
Tue, Jan 09, 2024 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside information: Faron Announce... |
| 03.01.2024 | Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Wed, Jan 03, 2024 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Faron Pharmaceuticals to Present at the 42nd Annual J.P. M... |
| 11.12.2023 | Phase 1 BEXMAB data presented at ASH | Phase 1 BEXMAB data presented at ASH
Mon, Dec 11, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th... |
| 27.10.2023 | Exercise of options | Exercise of options
Fri, Oct 27, 2023 08:15 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron”)
Exercise of options
Issue of equity
Company announcement, October 27, 2023 at 7:15 a.m. BST / 9:15 a.m. EEST
TURKU, FINLAND / BOSTON, M... |
| 27.10.2023 | Results of Placing | Results of Placing
Fri, Oct 27, 2023 08:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, IN... |
| 26.10.2023 | Proposed Issue and Placing | Proposed Issue and Placing
Thu, Oct 26, 2023 17:30 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY... |
| 11.10.2023 | Faron Announces Positive BEXMAB Study Update | Faron Announces Positive BEXMAB Study Update
Wed, Oct 11, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML a... |
| 03.10.2023 | Faron to host webcast on new BEXMAB study data | Faron to host webcast on new BEXMAB study data
Tue, Oct 03, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron to host webcast to discuss new data from Phase I/II BEXMAB Study of... |
| 22.09.2023 | Board Changes | Board Changes
Fri, Sep 22, 2023 17:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Board Changes
Company announcement, September 22, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, ... |
| 21.09.2023 | Faron Appoints Interim Chief Medical Officer | Faron Appoints Interim Chief Medical Officer
Thu, Sep 21, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
Dr. Marie-Louise Fjälls... |
| 08.09.2023 | Change in the Board of Directors | Change in the Board of Directors
Fri, Sep 08, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Change in the Board of Directors
Company announcement, September 8, 2023
TURKU, FINLAND / BOSTON, MA - Fa... |
| 06.09.2023 | Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Wed, Sep 06, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment... |
| 01.09.2023 | NOTICE OF FARON PHARMACEUTICALS LTD'S EXTRAORDINARY GENERAL MEETING | NOTICE OF FARON PHARMACEUTICALS LTD'S EXTRAORDINARY GENERAL MEETING
Fri, Sep 01, 2023 11:00 CET Report this content
NOTICE OF faron pharmaceuticals LTD’s extraordinary GENERAL MEETING
Shareholders of Faron Pharmaceuticals Ltd (the “Company”... |
| 31.08.2023 | Exercise of options, Directors Dealing, Issue of equity | Exercise of options, Directors Dealing, Issue of equity
Thu, Aug 31, 2023 15:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron”)
Exercise of options, Directors Dealing
Issue of equity
Company announcement, August 31, 2023 at 14:... |
| 29.08.2023 | FDA Orphan Drug Designation for Bexmarilimab | FDA Orphan Drug Designation for Bexmarilimab
Tue, Aug 29, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Inside Information: Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myel... |
| 29.08.2023 | Faron 2023 Half-Year Financial Results | Faron 2023 Half-Year Financial Results
Tue, Aug 29, 2023 08:01 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
Company Announcement, August 2... |
| 04.08.2023 | Notice of Half-Year Financial Results | Notice of Half-Year Financial Results
Fri, Aug 04, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or the “Company”)
Faron Pharmaceuticals
Notice of Half-Year Financial Results
Company Announcement, August 4, 2023
TUR... |
| 02.08.2023 | Faron to Participate at Canaccord Conference | Faron to Participate at Canaccord Conference
Wed, Aug 02, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
... |
| 25.07.2023 | Grant of options | Grant of options
Tue, Jul 25, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Grant of options
Company announcement, July 25, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN,... |
| 19.07.2023 | Faron to Hold BEXMAB Study Conference Call | Faron to Hold BEXMAB Study Conference Call
Wed, Jul 19, 2023 08:01 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Stud... |
| 19.07.2023 | BEXMAB study Update | BEXMAB study Update
Wed, Jul 19, 2023 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “the Company”)
Inside Information: Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refr... |
| 29.06.2023 | Announcement of Placing | Announcement of Placing
Thu, Jun 29, 2023 08:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, I... |
| 12.06.2023 | Exercise of options | Exercise of options
Mon, Jun 12, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “the Company”)
Exercise of options
Issue of equity
Company announcement, June 12, 2023
TURKU, FINLAND / BOSTON, MA – Faron Pharmaceutic... |
| 09.06.2023 | New biomarker data from BEXMAB study at EHA2023 | New biomarker data from BEXMAB study at EHA2023
Fri, Jun 09, 2023 09:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “the Company”)
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress B... |
| 05.06.2023 | Board Member to Assume Transactional Advisor Role | Board Member to Assume Transactional Advisor Role
Mon, Jun 05, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “the Company”)
Faron Board Member Leopoldo Zambeletti to Assume a Transactional Advisor Role within the C... |
| 24.04.2023 | Bexmarilimab Efficacy and Safety in MATINS Trial | Bexmarilimab Efficacy and Safety in MATINS Trial
Mon, Apr 24, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron or the Company")
Faron Announces Release of Research Confirming Bexmarilimab Efficacy and Safety in ... |
| 19.04.2023 | Bexmarilimab KOL Event | Bexmarilimab KOL Event
Wed, Apr 19, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron or the Company")
Bexmarilimab for Hematological Malignancies KOL Event
Press Release, April 19, 2023
TURKU, FINLAND / BOSTON, ... |
| 18.04.2023 | Poster Presentations at AACR 2023 | Poster Presentations at AACR 2023
Tue, Apr 18, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron Pharmaceuticals Announces Poster Presentations on Bexmarilimab at the American A... |
| 17.04.2023 | BEXMAB study update | BEXMAB study update
Mon, Apr 17, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
("Faron” or the “Company")
Inside Information: Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignanci... |
| 13.04.2023 | Faron at Canaccord Oncology Virtual Conference | Faron at Canaccord Oncology Virtual Conference
Thu, Apr 13, 2023 17:30 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Faron to Present at Canaccord Horizons in Oncology Virtual Conference
Press release, April 13... |
| 29.03.2023 | Appointment of Chief Financial Officer | Appointment of Chief Financial Officer
Wed, Mar 29, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Faron Appoints James O'Brien, CPA, MBA as Chief Financial Officer
Company announcement, March 29, 202... |
| 24.03.2023 | Results of AGM | Results of AGM
Fri, Mar 24, 2023 14:30 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or the “Company”)
Results of the Annual General Meeting and Decisions of the Board of Directors
Company announcement, March 24, 2023 at 15.30 (E... |
| 24.03.2023 | Board Change | Board Change
Fri, Mar 24, 2023 14:35 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Board Change
Company announcement, March 24, 2023 at 15.35 PM (EET) / 13.35 PM (GMT) / 09.35 AM (EDT)
TURKU, FINLAND / BOSTON, ... |
| 22.03.2023 | Positive FDA Feedback to Progress Bexmarilimab | Positive FDA Feedback to Progress Bexmarilimab
Wed, Mar 22, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Inside Information: Faron Announces Positive US Food and Drug Administration (FDA) Feedback t... |
| 03.03.2023 | Faron´s Annual Report 2022 Published | Faron´s Annual Report 2022 Published
Fri, Mar 03, 2023 08:15 CET Report this content
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron´s Annual Report 2022 Published
Company announcement, March 3, 2023 at 02:15 A... |
| 03.03.2023 | Financial Statement January 1 to December 31 2022 | Financial Statement January 1 to December 31 2022
Fri, Mar 03, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
Faron’s Financial Statement Release January 1 to December 31, 2022
Financial statement release March 3, 2023 at 09:00... |
| 03.03.2023 | Notice of Faron Pharmaceuticals Ltd’s AGM | Notice of Faron Pharmaceuticals Ltd’s AGM
Fri, Mar 03, 2023 10:00 CET Report this content
NOTICE OF faron pharmaceuticals LTD’s ANNUAL GENERAL MEETING
Shareholders of Faron Pharmaceuticals Ltd (the “Company”) are notified of the Annual Gene... |
| 06.02.2023 | Update to Faron’s Financial Calendar for 2023 | Update to Faron’s Financial Calendar for 2023
Mon, Feb 06, 2023 19:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Update to Faron’s Financial Calendar for 2023
Company announcement, February 6, 2023 at 1:00 PM (E... |
| 06.02.2023 | Notice of 2022 Full-Year Results and Annual Report | Notice of 2022 Full-Year Results and Annual Report
Mon, Feb 06, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or the “Company”)
Notice of 2022 Full-Year Results and Annual Report
Press release, February 6, 2023 at 02:... |
| 27.01.2023 | Results of Placing | Results of Placing
Fri, Jan 27, 2023 08:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, IN... |
| 26.01.2023 | Proposed Issue and Placing | Proposed Issue and Placing
Thu, Jan 26, 2023 17:30 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY... |
| 16.01.2023 | BEXMAB study update | BEXMAB study update
Mon, Jan 16, 2023 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron or Company”)
Inside Information: Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies
– BEXMAB Stud... |
| 23.12.2022 | Faron’s Financial Calendar for 2023 | Faron’s Financial Calendar for 2023
Fri, Dec 23, 2022 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Faron’s Financial Calendar for 2023
Company announcement, December 23, 2022 at 9.00 am (EET) / 07:00 AM (GMT... |
| 05.12.2022 | BEXMAB Study Update | BEXMAB Study Update
Mon, Dec 05, 2022 08:00 CET Report this content
Faron Pharmaceuticals Oy
(“Faron” or “Company”)
Inside Information: Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies
BEXMAB Study Up... |
| 01.12.2022 | Faron Appoints Maija Hollmén PhD as CSO | Faron Appoints Maija Hollmén PhD as CSO
Thu, Dec 01, 2022 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron or “Company”)
Faron Appoints Maija Hollmén, Ph.D., as Chief Scientific Officer
Company announcement, December 1, 2022... |
| 18.11.2022 | Amendment Terms and Conditions with IPF Partners | Amendment Terms and Conditions with IPF Partners
Fri, Nov 18, 2022 17:30 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron” or “Company”)
Inside Information: Amendment to Terms and Conditions of Warrants and Funding Agreement with ... |
